Natera, Inc. (NASDAQ:NTRA) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 10.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,971 shares of the medical research company's stock after purchasing an additional 5,270 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Natera were worth $8,067,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Natera by 43.7% during the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after buying an additional 2,036,396 shares in the last quarter. Norges Bank bought a new stake in Natera during the 4th quarter worth about $224,040,000. Raymond James Financial Inc. acquired a new stake in Natera in the 4th quarter valued at about $146,419,000. Finally, Vanguard Group Inc. raised its stake in shares of Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 2,018 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $152.18, for a total value of $307,099.24. Following the completion of the sale, the chief financial officer directly owned 73,539 shares in the company, valued at $11,191,165.02. This represents a 2.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 6,980 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $150.10, for a total value of $1,047,698.00. Following the transaction, the chief executive officer owned 185,182 shares in the company, valued at approximately $27,795,818.20. This represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,630 shares of company stock valued at $6,235,808. 7.60% of the stock is owned by corporate insiders.

Natera Stock Up 0.5%

NTRA stock traded up $0.85 during trading on Wednesday, hitting $161.57. 1,086,900 shares of the company's stock traded hands, compared to its average volume of 1,423,031. The firm has a market capitalization of $22.06 billion, a P/E ratio of -109.91 and a beta of 1.73. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The business has a fifty day simple moving average of $160.04 and a two-hundred day simple moving average of $158.53.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm's quarterly revenue was up 36.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.56) EPS. On average, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on NTRA. UBS Group raised their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Barclays boosted their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Royal Bank Of Canada initiated coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price on the stock. Finally, Morgan Stanley boosted their target price on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, Natera presently has an average rating of "Moderate Buy" and an average target price of $184.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.